A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) Patients
Primary Objective
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the MTD or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
Pathology - SOM
University of Colorado Hospital
Principal Investigator
Daniel Pollyea, MD, MS
Study ID
Protocol Number: 20-1388
More information available at ClinicalTrials.gov: NCT04372433
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers